LCB-84 is under clinical development by LigaChem Biosciences and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LCB-84’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LCB-84 overview

LCB-84 is under development for the treatment of solid tumors including colorectal cancer (CRC), gastric cancer (GC), non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and hematological cancer. The therapeutic candidate is an antibody-drug conjugate developed based on next-generation ADC (ConjuALL) platform technology. The therapeutic candidate is a TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug. It is administered through intravenous route.

LigaChem Biosciences overview

LigaChem Biosciences (LCB), formerly LegoChem Biosciences Inc, is a biotechnology company that discovery and development of novel therapeutics for infectious diseases, oncology, and immuno-oncology indications. The company is investigating antibody-drug conjugates (ADC) to treat non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), triple-negative breast cancer (TNBC), myelodysplastic syndromes (MDS) and other solid and hematological cancers. LCB is also developing antibiotics for gram-negative and gram-positive bacterial infections; anti-fibrotic against non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases and anticoagulants to treat coronary artery diseases and minimize the side effects of bleeding. The company works in partnership with pharmaceutical and biotechnology companies to discover new drugs. LCB is headquartered in Daejeon, South Korea.

For a complete picture of LCB-84’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.